Patents by Inventor Eric A. Vasiliauskas
Eric A. Vasiliauskas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8486640Abstract: A common long term problem after Ileal Pouch-Anal Anastomosis (IPAA) is the inflammation of the pouch, called pouchitis. Additionally, about 5-10% of patients undergoing IPAA with a diagnosis of ulcerative colitis at the time of surgery are subsequently diagnosed with Crohn's disease. In one embodiment, the present invention provides methods of diagnosing and predicting susceptibility to pouchitis after IPAA by detecting the presence or absence of pANCA and/or Cbir1 Flagellin expression.Type: GrantFiled: March 21, 2008Date of Patent: July 16, 2013Assignee: Cedars-Sinai Medical CenterInventors: Phillip R. Fleshner, Eric A. Vasiliauskas, Gil Melmed, Stephan R. Targan
-
Publication number: 20120208212Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.Type: ApplicationFiled: December 6, 2011Publication date: August 16, 2012Applicant: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
-
Patent number: 8163501Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.Type: GrantFiled: December 22, 2009Date of Patent: April 24, 2012Assignee: Cedars-Sinai MedicalInventors: Stephen R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
-
Publication number: 20100240077Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.Type: ApplicationFiled: December 22, 2009Publication date: September 23, 2010Applicant: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
-
Publication number: 20100105044Abstract: A common long term problem after Ileal Pouch-Anal Anastomosis (IPAA) is the inflammation of the pouch, called pouchitis. Additionally, about 5-10% of patients undergoing IPAA with a diagnosis of ulcerative colitis at the time of surgery are subsequently diagnosed with Crohn's disease. In one embodiment, the present invention provides methods of diagnosing and predicting susceptibility to pouchitis after IPAA by detecting the presence or absence of pANCA and/or Cbir1 Flagellin expression.Type: ApplicationFiled: March 21, 2008Publication date: April 29, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Phillip R. Fleshner, Eric A. Vasiliauskas, Gil Melmed, Stephan R. Targan
-
Patent number: 7662569Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.Type: GrantFiled: April 11, 2003Date of Patent: February 16, 2010Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
-
Publication number: 20050054021Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.Type: ApplicationFiled: November 26, 2003Publication date: March 10, 2005Inventors: Stephan Targan, Eric Vasiliauskas, William Mow, Huiying Yang, Phillip Fleshner, Jerome Rotter
-
Publication number: 20040203076Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.Type: ApplicationFiled: April 11, 2003Publication date: October 14, 2004Inventors: Stephan R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
-
Patent number: 5932429Abstract: Provided herein is a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibody (pANCA) is present in a patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis (UC). Also provided is a method of diagnosing a clinical subtype of Crohn's disease in a patient with CD by determining whether pANCA or speckling anti-pan polymorphonuclear antibody (SAPPA) is present in the patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis and where the presence of SAPPA indicates a clinical subtype of CD having perforating, fistulizing or small bowel obstructive disease.Type: GrantFiled: April 11, 1997Date of Patent: August 3, 1999Assignees: Cedars-Sinai Medical Center, Prometheus Laboratories Inc.Inventors: Stephan R. Targan, Eric A. Vasiliauskas, Scott E. Plevy, Mary J. Barry
-
Patent number: 5916748Abstract: The present invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibodies (pANCA) are present in a patient with CD, where the presence of pANCA indicates the clinical subtype of CD with features of ulcerative colitis (UC). The invention also provides a method of diagnosing a clinical subtype of CD by detecting an Arg.sup.241 allele at an ICAM-1 locus in a patient with CD, where the Arg.sup.241 allele indicates a clinical subtype of CD with features of ulcerative colitis. In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg.sup.241 allele at an ICAM-1 locus in a patient with CD, where the Arg.sup.241 allele indicates the pANCA-positive subtype of CD.Type: GrantFiled: August 15, 1996Date of Patent: June 29, 1999Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Eric A. Vasiliauskas, Scott E. Plevy, Huiying Yang, Jerome I. Rotter
-
Patent number: 5874233Abstract: The present invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibodies (pANCA) are present in a patient with CD, where the presence of pANCA indicates the clinical subtype of CD with features of ulcerative colitis (UC). The invention also provides a method of diagnosing a clinical subtype of CD by detecting an Arg.sup.241 allele at an ICAM-1 locus in a patient with CD, where the Arg.sup.241 allele indicates a clinical subtype of CD with features of ulcerative colitis. In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg.sup.241 allele at an ICAM-1 locus in a patient with CD, where the Arg.sup.241 allele indicates the pANCA-positive subtype of CD.Type: GrantFiled: August 15, 1996Date of Patent: February 23, 1999Assignee: Cedars-Sinai Medical CenterInventors: Stephan R. Targan, Eric A. Vasiliauskas, Scott E. Plevy